The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.

The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.

EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.